Cart
sales@molnova.com
CEP-33779
CAS No. 1257704-57-6
CEP-33779( CEP33779 | CEP-33779 | CEP 33779. )
Catalog No. M11060 CAS No. 1257704-57-6
CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 49 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 132 | In Stock |
|
| 25MG | 231 | In Stock |
|
| 50MG | 356 | In Stock |
|
| 100MG | 530 | In Stock |
|
| 500MG | 1152 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCEP-33779
-
NoteResearch use only, not for human use.
-
Brief DescriptionCEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
-
DescriptionCEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
-
In Vitro——
-
In Vivo——
-
SynonymsCEP33779 | CEP-33779 | CEP 33779.
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK2,JAK3
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number1257704-57-6
-
Formula Weight462.57
-
Molecular FormulaC24H26N6O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO:93 mg/mL (201.05 mM); Ethanol:<1 mg/mL (<1 mM); Water：<1 mg/mL (<1 mM)
-
SMILESO=S(C1=CC=C(C2=CC=CN3C2=NC(NC4=CC=CC(N5CCN(C)CC5)=C4)=N3)C=C1)(C)=O
-
Chemical NameN-(3-(4-methylpiperazin-1-yl)phenyl)-8-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dugan BJ, et al. A selective, orally bioavailable 1,2,4-triazolo1,5-apyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779. J Med Chem. 2012 Jun 14;55(11):5243-54.
2. Seavey MM, et al. Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. Mol Cancer Ther. 2012 Apr;11(4):984-93.
molnova catalog
related products
-
Pumecitinib
Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.
-
TG-101209
A potent, selective, orally bioavailable JAK2 inhibitor with IC50 of 6 nM; also inhibits FLT3 (IC50=25 nM) and RET (IC50=17 nM) kinases, weakly inhibits JAK3 (IC50=168 nM).
-
BD750
BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in mouse and human T cells, respectively).
